Smith+Nephew and U.S. Army Institute of Surgical Research to engage in Master Cooperative Research and Development Agreement
28 Fevereiro 2024 - 10:00AM
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology
company, today announced they have entered into a Master
Cooperative Research and Development Agreement (CRADA) with the
U.S. Army Institute of Surgical Research (USAISR). This marks the
first time that the USAISR has entered into a master agreement of
this nature with an industry-leading medical technology
company.
The Master CRADA represents an enterprise-wide opportunity for
Smith+Nephew across all business units - Advanced Wound Management,
Orthopaedics and Sports Medicine - to enter into multiple
collaborative research efforts.
“Smith+Nephew has a rich history supporting the military and
partnering with the USAISR on this agreement furthers our purpose
of helping people live their Life Unlimited,” said Rohit Kashyap,
President, Advanced Wound Management and Commercial Operations at
Smith+Nephew. “This agreement is exciting on many levels - not just
for Smith+Nephew, but for our customers and their patients as
well.”
The agreement enables efficient collaboration and strengthens
the relationship between the USAISR and Smith+Nephew for future
research endeavours in diverse areas of mutual interest. These
types of cooperative efforts benefit both the Department of Defense
(DOD) and industry leaders by providing opportunities to conduct
joint research and learn from each other.
“The pre-negotiated key terms and conditions of the Master CRADA
provide the broad legal framework under which for multiple, future
collaborative research efforts will be assigned. In addition to
streamlining the research agreement process, this Master CRADA
provides the foundation for a strategic, joint effort to leverage
the infrastructure, expertise, and capabilities of both parties to
support innovation that aims to address technical challenges to
improving combat casualty care,” said COL (Dr.) J. Brian Lanier,
Commander, U.S. Army Institute of Surgical Research (USAISR).
- ends -
Enquiries
MediaDavid
Snyder
+1
978-749-1440Smith+Nephew |
|
|
|
|
|
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused
on the repair, regeneration and replacement of soft and hard
tissue. We exist to restore people’s bodies and their self-belief
by using technology to take the limits off living. We call this
purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission
every day, making a difference to patients’ lives through the
excellence of our product portfolio, and the invention and
application of new technologies across our three global
business units of Orthopaedics, Sports Medicine & ENT and
Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100
countries, and generated annual sales of $5.5 billion in 2023.
Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN).
The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith
& Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please visit
www.smith-nephew.com and follow us on X, LinkedIn, Instagram
or Facebook.
Forward-looking Statements This document
may contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth
and trading profit margins, market trends and our product pipeline
are forward-looking statements. Phrases such as "aim", "plan",
"intend", "anticipate", "well-placed", "believe", "estimate",
"expect", "target", "consider" and similar expressions are
generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: conflicts
in Europe and the Middle East, economic and financial conditions in
the markets we serve, especially those affecting healthcare
providers, payers and customers; price levels for established and
innovative medical devices; developments in medical technology;
regulatory approvals, reimbursement decisions or other government
actions; product defects or recalls or other problems with quality
management systems or failure to comply with related regulations;
litigation relating to patent or other claims; legal and financial
compliance risks and related investigative, remedial or enforcement
actions; disruption to our supply chain or operations or those of
our suppliers; competition for qualified personnel; strategic
actions, including acquisitions and disposals, our success in
performing due diligence, valuing and integrating acquired
businesses; disruption that may result from transactions or other
changes we make in our business plans or organisation to adapt to
market developments; relationships with healthcare professionals;
reliance on information technology and cybersecurity; disruptions
due to natural disasters, weather and climate change related
events; changes in customer and other stakeholder sustainability
expectations; changes in taxation regulations; effects of foreign
exchange volatility; and numerous other matters that affect us or
our markets, including those of a political, economic, business,
competitive or reputational nature. Please refer to the documents
that Smith+Nephew has filed with the U.S. Securities and Exchange
Commission under the U.S. Securities Exchange Act of 1934, as
amended, including Smith+Nephew's most recent annual report on Form
20-F, which is available on the SEC’s website at www. sec.gov, for
a discussion of certain of these factors. Any forward-looking
statement is based on information available to Smith+Nephew as of
the date of the statement. All written or oral forward-looking
statements attributable to Smith+Nephew are qualified by this
caution. Smith+Nephew does not undertake any obligation to update
or revise any forward-looking statement to reflect any change in
circumstances or in Smith+Nephew's expectations.
◊ Trademark of Smith+Nephew. Certain marks registered in US
Patent and Trademark Office.
Smith and Nephew (NYSE:SNN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Smith and Nephew (NYSE:SNN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024